Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Synagis

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
  • R. Wang, Ying Wang, +15 authors F. Wang
  • Proceedings of the National Academy of Sciences
  • 2016
  • Corpus ID: 4922802
Significance There is considerable interest in developing immunosuppressants that can specifically target effector memory T cells… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
2015
2015
Intramuscular injections are contra-indicated in infants with either acquired or congenital bleeding disorders. In such patients… Expand
2013
2013
1. A method for isolating Synagisiz composition comprising Synagis, the method comprising: i. carrying out an ion exchange… Expand
2013
2013
The present invention has for its object a method for separating an antibody from a composition. In some embodiments, this method… Expand
2009
2009
Infants receive many painful immunizations before they are 2 years old. The purpose of this study was to evaluate if topical… Expand
  • table 1
Review
2009
Review
2009
  • R. Giusti
  • Pediatric pulmonology
  • 2009
  • Corpus ID: 5937001
 
2003
2003
DESCRIPTION: Synagis® (palivizumab) is a humanized monoclonal antibody (IgG1κ ) produced by recombinant DNA technology, directed… Expand
Review
2002
Review
2002
Palivizumab (Synagis; Abbott Laboratories), a humanized, monoclonal antibody, prevents lower respiratory tract infection by… Expand
2001
2001
Respiratory Syncytial Virus (RSV) can be devastating to premature infants and children with chronic lung disease. Palivizumab… Expand
2000
2000
To the Editor. The continuing reports, letters, and pharmacoeconomic analyses concerning the use of expensive respiratory… Expand